| Document |
Document Title |
|
JP2018502159A |
The present invention has published a series of BTK inhibitors. Specifically, a compound represented by the formula (I), the formula (II), the formula (III) or the formula (IV), a pharmaceutically acceptable salt thereof, a tautomer ther...
|
|
JP6186438B2 |
The present invention relates to benzoimidazole-carboxylic acid amide compounds of the formula I, in which R′, R″, R′″, R1, R2, R3, R4, R5, R6 and Z are defined as indicated below. The compounds of the formula I are APJ receptor ...
|
|
JP6162133B2 |
Disclosed are derivatives of protoberberine biological alkaloids or physiologically acceptable salts thereof produced by means of a derivative reaction of a source material of biological alkaline quaternary ammonium salts of protoberberi...
|
|
JP6126102B2 |
Pure S-(−)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-m
ethyl-1-oxo-1H,-5H-benzo[i,j]quinolizine-2-carboxylic acid L-arginine salt tetrahydrate and a process for its preparation is disclosed.
|
|
JP2017504633A |
The present invention is R1, R2, R3, R4, R5And R6Is as described herein in general formula (I).Provided are novel compounds having, compositions containing compounds, and methods of using compounds in the treatment of hepatitis B virus.
|
|
JP2016538304A |
The present invention provides inhibitors of hypoxia-inducing factors (HIF), as well as their use in the prevention or inhibition of diseases characterized by abnormal HIF activity or levels, such as tumor progression, and in the treatme...
|
|
JP2016196487A |
To provide a novel benzoquinolone compound having a vesicle monoamine transporter 2 (VMAT2) inhibitory action, and capable of avoiding side effects accompanying oxidative metabolism observed in dihydrotetrabenazine which is an existing m...
|
|
JP5970037B2 |
The compound or a salt thereof, wherein each position represented as D has deuterium enrichment of no less than 10%.
|
|
JP5969004B2 |
A compound having the following general formula (I): wherein: X is a nitrogen atom and Y is a carbon atom; or X is a carbon atom and Y is a nitrogen atom; the Ar group is an aryl or heteroaryl group; and the RN and RN' groups, together w...
|
|
JP2016516683A |
Preferably, a method for increasing the rate of phosphine oxide reduction during the Wittig reaction is provided, including the use of acid additives. The reduction rate of room temperature catalytic Wittig reaction (CWR) phosphine oxide...
|
|
JP2016516018A |
One mode of the present invention provides the new high penetration constituent (HPC) or high penetration prodrug (HPP) for the medical treatment of Parkinson's disease. Since HPC/HPP may be changed into parent active medicine or a drug ...
|
|
JP5799011B2 |
The present invention provides a mangiferin-berberine salt and manufacturing method thereof. Otherwise, the present invention also provides the use of mangiferin- berberine salt as AMPK activator.
|
|
JP5778145B2 |
13-substituted 5,6-dihydrodibenzo[a,g]quinolizinium salt compounds of the general formula (I): processes for the preparation of said compounds, pharmaceutical compositions containing said compounds and the use of said compounds for the m...
|
|
JP5770102B2 |
In one aspect, the present invention provides for a compound of Formula I in which the variable X1a, X1b, X1c, X1d, Q, A, R1, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present inven...
|
|
JP2015110563A |
To provide a novel metomidate derivative compound having increased selectivity for CYP11B2 over CYP11B1.This invention provides a compound represented by a predetermined general formula or salt thereof.
|
|
JP5652918B2 |
The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl subs...
|
|
JP5615261B2 |
A compound represented by formula (I). (In the formula, X, X1, X2, X3, Z1 and Z2 are as defined in the description.)
|
|
JP5616345B2 |
The compound or a salt thereof, wherein each position represented as D has deuterium enrichment of no less than 10%.
|
|
JP5597835B2 |
|
|
JP5551711B2 |
The present technology relates to compounds of Formulas (V) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis,...
|
|
JP2014129347A |
To provide a composition, a film containing the composition, and an electronic device containing the composition.The composition comprises a tetraphenylene ethylene having a structure of either of the examples 1 to 25, a tetraphenylene e...
|
|
JP2014122246A |
To provide a method of manufacturing a Magnoliidae compound.A Magnoliidae compound is produced by obtaining a part of Magnoliidae plant. The part of Magnoliidae plant is mixed with alcohol and water. The mixture of the part of Magnoliida...
|
|
JP5392622B2 |
This invention relates to a method of imaging vesicular monoamine transporters and to labeled compounds and pharmaceutical compositions thereof, and methods of making labeled compounds useful in imaging vesicular monoamine transporters. ...
|
|
JP5359100B2 |
To provide a new oxime ester compound that can function as a highly sensitive radical polymerization initiator, and a curable composition using the same. The compound is represented by general formula (1) (wherein R1-R5are each a hydroge...
|
|
JP5255183B2 |
The invention relates to crystalline S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-met
hyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid L-arginine salt tetrahydrate, a process for its preparation and pharmaceutical form...
|
|
JPWO2011078030A1 |
Provided is a novel photochromic compound having a neutral color tone at the time of color development, a small initial coloration, a high color development density, a high fading rate, and good durability. The photochromic compound is a...
|
|
JP5172849B2 |
The present invention relates to a process of the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one of the formula by employing a dialkylmalonate of the formula wherein R1b is lower alkyl, and the use of this process for the manufact...
|
|
JP5169821B2 |
[Problem] To provide a compound having excellent platelet aggregation inhibitory activity. [Means for Resolution] It was found that quinolone derivatives characterized in that these have lower alkyl, cycloalkyl or the like at the 1-posit...
|
|
JP5153329B2 |
Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker grou...
|
|
JP5113751B2 |
Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis,...
|
|
JP5049441B2 |
The present invention relates to novel compounds of the formula (I) in which W, X, Y, Z, G, A, B, Q1, Q2 and D are each as defined in the disclosure, to a plurality of processes for their preparation and to their use as pesticides and he...
|
|
JP4999334B2 |
To provide a compound which can be manufactured at a low cost and easily, and which gives a photoelectric transducer having high photoelectric conversion efficiency also in a long wavelength range of at least 600 nm. The compound is show...
|
|
JP2012514655A |
Fluorinated compounds and methods of making fluorinated compounds are described herein.
|
|
JP2012097072A |
To provide a pharmaceutical composition composed of the extracts of a plurality of crude drugs, which causes reduced side-effects and has high safety while exhibiting an excellent antibacterial action and has urease inhibitory activity, ...
|
|
JP4902913B2 |
|
|
JP4888750B2 |
To confirm effects such as antimicrobial activity, suppression of uresase activity, intragastric fixability and interleukin-8 generation, or the like, against Helicobacter pylori which is a pathogen of gastritis, gastric ulcer and duoden...
|
|
JP4874454B2 |
|
|
JP4853824B2 |
To provide a medicinal composition having excellent inhibitory actions on platelet aggregation. A quinolone derivative having an amide group at the 3-position and a substituted amino group substituted with a substituent having a cyclic s...
|
|
JP4853837B2 |
N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxa
mide is effective for treating IBS. In addition, IBS may be effectively treated with N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxa
mide when used concomitantly w...
|
|
JP4815566B2 |
The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonist and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides phar...
|
|
JP4796698B2 |
The present invention relates to novel compounds which are protein kinase C inhibitors, methods for their preparation, intermediates therefor and pharmaceutical compositions comprising them. More particularly, the present invention relat...
|
|
JP4790703B2 |
There is provided a CRF receptor antagonist comprising a compound of the formula (I) : A-W-Ar wherein, A is a group represented by the formula (A2), wherein ring Ab is a 5- or 6- membered ring which may be further substituted in addition...
|
|
JP2011524894A |
The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are defined herein, to compositions containing such compounds and to the uses of such comp...
|
|
JP2011162553A |
To provide one form of a crystalline S-(-)-9-fluoro-6, 7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i, j]quinolizine-2-carboxylic acid L-arginine salt having excellent properties.The invention relates to crystalline ...
|
|
JP4754699B2 |
To provide an organic compound having absorption maximum in visible region, emitting visible light in red color area by exciting the compound and useful as a luminous agent and a light absorbent in organic electroluminescent element or t...
|
|
JP4741799B2 |
The present invention relates to novel 1,2,3-substituted indolizine derivative which are inhibitors of fibroblast growth factors, to methods or preparing such derivatives, to pharmaceutical compositions comprising such derivatives, and t...
|
|
JP2011519938A |
Disclosed herein are compounds represented by the structural formula: therapeutic methods, compositions, and medicaments related thereto are also disclosed.
|
|
JP4718467B2 |
The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
|
|
JP2011126792A |
To provide a medicament effective for intractable inflammatory disease such as septicemia, and to provide an application thereof.It is discovered that the dehydrocorydaline of one component of Corydalis turtschaninovii macrophage-specifi...
|
|
JP2011517312T |
The present invention provides a new full オロアルキルテトラベナ gin carbinol compound. A full オロアルキルテトラベナ gin carbinol compound is provided with both a racemic form and a form wealth-ized in enantiomorph...
|
